REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Great Novel Therapeutics Biotech & Medic (Taiwan, China)

Main Activities: Research and Development in Biotechnology (except Nanobiotechnology)
Full name: Great Novel Therapeutics Biotech & Medic Profile Updated: July 08, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

GNT Biotech & Medicals Corporation is mainly engaged in the research and development of innovative drugs to treat advanced cancers. The company was established in 2013 and is headquartered in Taiwan.

Headquarters
16F.-5, No. 508, Sec. 7, Zhongxiao E. Rd, Nangang Dist
Taipei City; Taipei City;

Contact Details: Purchase the Great Novel Therapeutics Biotech & Medic report to view the information.

Basic Information
Total Employees:
Purchase the Great Novel Therapeutics Biotech & Medic report to view the information.
Outstanding Shares:
Purchase the Great Novel Therapeutics Biotech & Medic report to view the information.
Financial Auditors:
Purchase the Great Novel Therapeutics Biotech & Medic report to view the information.
Incorporation Date:
April 03, 2013
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Vice President
Ownership Details
Purchase this report to view the information.
3.36%
Purchase this report to view the information.
3.01%
Purchase this report to view the information.
2.81%
Purchase this report to view the information.
1.69%
Purchase this report to view the information.
0.66%
Company Performance
Financial values in the chart are available after Great Novel Therapeutics Biotech & Medic report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Net sales revenue
-88.93%▼
Total operating revenue
-88.85%▼
Operating profit (EBIT)
-79.96%▼
EBITDA
-87.31%▼
Net Profit (Loss) for the Period
-81.98%▼
Total assets
2.13%▲
Total equity
4.66%▲
Operating Profit Margin (ROS)
-11586%▼
Net Profit Margin
-11041.94%▼
Return on Equity (ROE)
-3.93%▼
Quick Ratio
13.63%▲
Cash Ratio
9.8%▲

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo